Researchers advanced the therapy with an AI platform that uses machine learning models trained on patient endotyping, multiomics, biomarker, and clinical data. The US Food and Drug Administration (FDA ...

The most important of the tested treatment benefits was reducing the risk of death, while the least important was the ability to easily take a bath or shower. People living with transthyretin-mediated ...

(Getty Images/ janiecbros) Olverembatinib treatment plus low-intensity chemotherapy showed efficacy in patients with newly diagnosed Philadelphia chromosome-positive ALL. The vast majority (94.4%) of ...

The mixed vascular-fibrotic group demonstrated the shortest median progression-free survival (36 months) and the highest independent risk of disease progression. Researchers proposed a new ...

Julian Beach, MHRA executive director, said the agency had assessed the evidence and was “satisfied it meets our standards for safety, quality, and effectiveness.” The UK Medicines and Healthcare ...

The majority (74%) of patients with PBC treated with seladelpar achieved composite alkaline phosphatase normalization at 24 months. Seladelpar treatment is associated with high and sustained rates of ...

Three‐dimensional imaging revealed a loss of normal microvascular architecture, areas of hyper- and hypovascularization, and microvascular obstruction due to capillary thrombosis.

All 24 participants in the phase 1b trial maintained their baseline motor milestones, and half achieved at least 1 new WHO motor milestone after salanersen treatment. The US Food and Drug ...

Arm span gains of 9.4 cm in treatment-naive and 7.9 cm in navepegritide-experienced children over 52 weeks surpassed the natural history trend for untreated children with achondroplasia. Children with ...

In a pooled analysis of 48 emulated trials, the mortality risk was 69.7% lower among individuals who received an exon-skipping therapy plus glucocorticoids than among those who received ...